AcelRx Pharmaceuticals Inc (R5XA.SG)
| Previous close | 0.9310 |
| Open | 0.9240 |
| Bid | 0.9210 x N/A |
| Ask | 0.9780 x N/A |
| Day's range | 0.9210 - 0.9240 |
| 52-week range | 0.3745 - 1.3320 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireTalphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in conn
- PR Newswire
Talphera to Participate at A.G.P. Virtual Healthcare Conference
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.
- PR Newswire
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2024 financial results and provided a corporate update.
